Dymista nasal spray for allergies in Chinese teens
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests Dymista, a nasal spray combining an antihistamine and steroid, in teenagers aged 12–17 with moderate-to-severe allergic rhinitis (nasal allergies that disrupt sleep, school, or daily life). The study will see how well it works and if it's safe for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12–17 years old and of Chinese ethnicity
- You have moderate-to-severe allergic rhinitis (hay fever or year-round allergies) that affects your sleep, schoolwork, sports, or daily activities
- You've had a positive allergy test (skin prick test or blood test) in the past year showing you're allergic to something in your environment
- You have active allergy symptoms on the day you join the study
- You're willing to stop allergy medications for a few days to weeks before starting and to keep a daily diary during the trial
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called MG-K10 for people with moderate-to-severe seasonal hay fever that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it can reduce your allergy symptoms over the pollen season.
This study tests a new nasal spray (PG-011) for adults with moderate-to-severe seasonal allergies (hay fever). It compares the spray to a placebo to see if it reduces nasal symptoms like stuffiness, sneezing, and runny nose.
This study tests a new nasal spray (DEP114) to see if it helps control moderate to severe allergic rhinitis symptoms in children. It compares the spray to a standard steroid nasal spray.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This trial tests a new nasal spray for people with perennial (year-round) allergic rhinitis. It aims to see if the medicine works well and is safe compared to other treatments.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
Hear when a new Allergic Rhinitis Due to Allergens trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.